Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes

Keyphrases

• Crohn's Disease 100%
• Adverse Outcomes 100%
• Biologic Therapy 100%
• Mesalamine 100%
• Anti-tumor Necrosis Factor Therapy 36%
• Adjusted Hazard Ratio 27%
• Adverse Clinical Events 27%
• United States 18%
• Anti-tumor Necrosis Factor Agents 18%
• Denmark 9%
• Non-associated 9%
• Health Registers 9%
• AIMS™ 9%
• National Population 9%
• Hospitalization 9%
• National Database 9%
• Disease-related 9%
• Sensitivity Analysis 9%
• Retrospective Analysis 9%
• Population-based Cohort 9%
• Cox Regression Model 9%
• Anti-tumor Necrosis Factor (anti-TNF) 9%
• Clinical Factors 9%
• Multivariable Cox Regression 9%
• Healthcare Utilization 9%
• Clinical Health 9%
• Immunomodulator 9%
• MarketScan 9%
• Corticosteroid Use 9%
• National Health Insurance Research Database (NHIRD) 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Outcome 100%
• Crohn's Disease 100%
• Aminosalicylic Acid 100%
• Tumor Necrosis Factor 45%
• Tumor Necrosis Factor Inhibitor 18%
• Prospective Study 9%
• Immunomodulating Agent 9%